Robert Marcus
Stock Analyst at JP Morgan
(1.49)
# 3,407
Out of 5,182 analysts
24
Total ratings
55.56%
Success rate
-0.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $175 | $149.52 | +17.04% | 11 | Feb 10, 2026 | |
| PEN Penumbra | Upgrades: Overweight | $275 → $370 | $325.99 | +13.50% | 5 | Dec 18, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $10.74 | +598.32% | 2 | Dec 17, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $119.63 | -58.20% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $101.26 | -85.19% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $28.46 | +100.28% | 2 | Jul 29, 2020 |
Becton, Dickinson and Company
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $175
Current: $149.52
Upside: +17.04%
Penumbra
Dec 18, 2025
Upgrades: Overweight
Price Target: $275 → $370
Current: $325.99
Upside: +13.50%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $10.74
Upside: +598.32%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $119.63
Upside: -58.20%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $101.26
Upside: -85.19%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $28.46
Upside: +100.28%